About Us
Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
)
Telix completes acquisition of European radiopharmaceutical production facility
Melbourne (Australia) – 3 April 2020. Telix is pleased to announce it has now completed the acquisition of a licensed...
Telix Pharmaceuticals Enters Commercial Distribution Agreement for Prostate Cancer Diagnostic
Indianapolis IN and Columbus OH (U.S.A) – 8 April 2020. Telix Pharmaceuticals (U.S.) Inc. is pleased to announce it has...
Positive FDA Feedback on NDA Submission Process for TLX591-CDx (kit for the preparation of 68Ga-PSMA-11)
Melbourne (Australia) – 25 Feb 2020. Telix Pharmaceuticals announces that it has received positive feedback from the FDA regarding its...
Telix Pharmaceuticals and partners receive $500K research grant from Government funded Innovative Manufacturing CRC
Melbourne (Australia) – 16 Mar 2020. Telix and partners receive $500K research grant from Government-funded Innovative Manufacturing CRC to advance...